Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00275899
Status:
UNKNOWN
Last Update Posted:
2006-01-12
First Post:
2006-01-11
Brief Title:
Role of DcR3 in T Cell Activation in SLE and RA
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Role of DcR3 in T Cell Activation in SLE and RA
Status:
UNKNOWN
Status Verified Date:
2005-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Decoy receptor 3 DcR3 a new member of tumor necrosis factor receptor TNFR superfamily is a decoy receptor for FasL and could inhibit FasL-induced apoptosis has recently been shown to induce costimulation of T cells Systemic lupus erythematosus SLE is an autoimmune disease with pathogenic autoantibodies and immune complexes results from abnormal immune responses including T and B lymphocyte hyperactivity and formation of pathogenic subsets of autoantibodies Rhematoid arthritis RA is a multi-systemic autoimmune disease characterized by persistent inflammatory synovitis Activated T lymphocytes infiltration to synovium is strongly correlated with the symptoms DcR3 mRNA is expressed in peripheral-blood T cells and is up-regulated after antigenic stimulation The DcR3 gene has been demonstrated to be overexpressed in patients with sclerosis or SLE however role of DcR3 in SLE and RA as well as the effects of DcR3 on T cell immune response is still not clear This study is to investigate role of DcR3-induced T cell activation in SLE and RA The genetic polymorphisms of DcR3 in association with SLE and RA will be studied to elucidate the genetic factors associated with development of SLE and RA For further explore the possible molecular mechanisms of elevated DcR3 in association with SLE we attempt to study whether DcR3 could induce T cell activation via costimualtion andor inhibit the activation induced cell death AICD of activated T cells in SLE and RA This study will provide a new direction of therapy in reverse T cell hyper-reactivity in SLE and RA
Detailed Description:
Specific Aim 1 Study DcR3-induced T cell activation in SLE and RA A Patients and controls Patients with SLE and RA in Department of Internal Medicine National Taiwan University Hospital will be studied All patient meet the criteria of the American College of Rheumatologists for diagnosis of SLE and RA As controls 20 healthy age- and gender-matched volunteers will be used All the studies including samples involving human is in accordance with institutional guidelines
B Detection of serum DcR3 protein in SLE and RA patients C T cell proliferation assay
Specific Aim 2 Study effects of DcR3 on activation-induced cell death AICD in SLE and RA In order to understand whether DcR3 could reduce the AICD in activated T cells in SLE and RA patients the T cells from these patients will be assayed their AICD in the presence and absence of soluble DcR3-Fc
Specific Aim 3 To investigate the association of clinical manifestation of SLE and RA with genetic polymorphism on DcR3 genes
A The gene sequencing and single nucleotide polymorphism SNP analysis of DcR3 genes
B The association of clinical manifestation of SLE and RA with genetic polymorphism on DcR3 genes
B Detection of serum DcR3 protein in SLE and RA patients C T cell proliferation assay
Specific Aim 2 Study effects of DcR3 on activation-induced cell death AICD in SLE and RA In order to understand whether DcR3 could reduce the AICD in activated T cells in SLE and RA patients the T cells from these patients will be assayed their AICD in the presence and absence of soluble DcR3-Fc
Specific Aim 3 To investigate the association of clinical manifestation of SLE and RA with genetic polymorphism on DcR3 genes
A The gene sequencing and single nucleotide polymorphism SNP analysis of DcR3 genes
B The association of clinical manifestation of SLE and RA with genetic polymorphism on DcR3 genes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None